

SEXUAL DYSFUNCTION AND IMPOTENCE**Effective Date:** September 1, 2025**Review Dates:** 1/93, 12/98, 12/00, 12/01, 11/02, 11/03, 11/04, 10/05, 10/06, 7/07, 2/08, 2/09, 2/10, 2/11, 2/12, 4/12, 4/13, 5/14, 5/15, 5/16, 5/17, 5/18, 5/19, 5/20, 5/21, 5/22, 8/22, 8/23, 8/24, 8/25**Date Of Origin:** July 16, 1990**Status:** Current**Summary of Changes****Changes:**

- For Medicaid members: Penile Implant Insertion is medically necessary when InterQual criteria are met.

Additions:

- New sections: Government Regulations, and Guidelines/Position Statements.

Deletion:

- I.C.1.a.i: Removed “effective 1/1/2023”

I. POLICY/CRITERIA**A. Evaluation of impotence is covered as a medical service.**

1. Appropriate diagnostic tests for impotence include tests to:
 - a. Determine if the cause of impotency is organic or non-organic.
 - b. Measure blood pressure and blood flow in the penis.
 - c. Evaluate the condition of blood vessels leading to the penis.
 - d. Determine if the nerve supply to the penis is adequate.

B. Treatment with insertion of a penile prosthesis is covered as a medical service.

1. Penile prosthesis implantation.
 - a. Medicaid members: May be medically necessary if InterQual criteria (Penile Implant Insertion) are met.
 - b. Coverage is provided for only one penile prosthesis implantation per member lifetime.

C. Treatment with drugs is not a covered benefit unless the member’s contract has a rider for coverage.

1. Drug Therapy (oral, injectable, pellets):
 - a. Drug therapy is not a covered benefit unless:
 - i. The drug is covered as standard on a Priority Health formulary that applies to the member, OR
 - ii. The Sexual Dysfunction Rider is a part of the member’s contract.
2. Medicaid members: Drug therapy is not a covered benefit as governed by State and Federal regulations.

D. The treatment of impotence with equipment is covered at the Durable Medical Equipment (DME) benefit level.

1. External Penile Erectile Vacuum Devices:
 - a. External penile erectile vacuum devices are covered at the Durable Medical Equipment benefit level. Coverage requirements include:
 - i. Member at least 18 years of age with a diagnosis of organic erectile dysfunction (ED).
 - ii. An appropriate evaluation must be done to determine the necessity for the external penile vacuum pump. This would include, but is not limited to:
 - o Medical, psychosocial and sexual history;
 - o Physical examination; and
 - o Laboratory and diagnostic evaluation. The laboratory testing should be thorough enough to identify comorbid conditions that may predispose the member to ED and that may contraindicate certain therapies. The effect of the member's other medications on ED should also be considered.
 - iii. Member has the manual dexterity to utilize the device.
 - iv. Adequate penile blood supply is present.
 - v. Devices are most effective in partial impotence.
 - vi. Contraindicated in patients with blood dyscrasias, including sickle cell disease, or those taking anticoagulants. Coverage is provided for only one external penile vacuum pump per member lifetime under the DME benefit.
 2. Clitoral therapy devices (e.g., Eros) are covered under the Medical Supply or Durable Medical Equipment (DME) benefit. Priority Health will provide coverage if there is a documented underlying disease/condition.
 - a. Indications for use of the Eros device include:
 - i. Greater clitoral and genital engorgement
 - ii. Increased vaginal lubrication
 - iii. Enhanced ability to achieve orgasm
 - iv. Improved overall sexual satisfaction
 - b. Clitoral therapy devices are **NOT** a covered benefit for Medicaid members.
- E. Coverage is not provided for:
- a. Psychological counseling for ED
 - b. Exogenous testosterone replacement therapy given solely for ED
 - c. Extracorporeal shock wave therapy for Peyronie's disease
 - d. Stem Cell Therapy for erectile dysfunction is experimental and investigational and is not a covered benefit.

II. GOVERNMENT REGULATIONS

CMS Coverage Determinations	Title and Number
National Coverage Determinations (NCDs)	<u>Diagnosis and Treatment of Impotence</u> , NCD 230.4

Local Coverage Determinations	N/A
--------------------------------------	-----

III. GUIDELINES/POSITION STATEMENTS

Medical or Professional Society	Recommendation
American College of Obstetricians and Gynecologists	Female Sexual Dysfunction, Practice Bulletin Number 213, July 2019
American Urological Association (AUA)	Erectile Dysfunction: AUA Guideline (2018)

IV. MEDICAL NECESSITY REVIEW

Prior authorization for certain drug, services, and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service, or procedure is medically necessary. For more information, please refer to the [Priority Health Provider Manual](#).

V. APPLICATION TO PRODUCTS

Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable.

- ❖ **HMO/EPO:** *This policy applies to insured HMO/EPO plans.*
- ❖ **POS:** *This policy applies to insured POS plans.*
- ❖ **PPO:** *This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.*
- ❖ **ASO:** *For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.*
- ❖ **INDIVIDUAL:** *For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.*
- ❖ **MEDICARE:** *Coverage is determined by the Centers for Medicare and Medicaid Services (CMS) and/or the Evidence of Coverage (EOC); if a coverage determination has not been adopted by CMS, this policy applies.*
- ❖ **MEDICAID/HEALTHY MICHIGAN PLAN:** *For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_42542_42543_42546_42551-159815--,00.html. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: http://www.michigan.gov/mdch/0,1607,7-132-2945_5100-87572--,00.html, the Michigan Medicaid Provider Manual will govern. If there is a discrepancy or lack of guidance in the Michigan Medicaid Provider Manual, the Priority Health contract with Michigan Medicaid will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.*

VI. DESCRIPTION

Erectile dysfunction (ED) is defined as the consistent or recurrent inability of a man to attain and maintain an erection sufficient for sexual intercourse (McCabe, 2016). ED may be organic in nature, that is, caused by a detectable physiological or structural change. A medication review is imperative during the assessment period, since ED cases may be caused by medications, including over-the counter preparations. The likelihood of erectile dysfunction increases with age but is not an inevitable consequence of aging.

Likely causes of male erectile dysfunction, based on clinical presentation, are listed in Appendix A. Treatment will vary depending on the severity and cause of the dysfunction. In the case of uncomplicated ED, treatment usually consists of oral medication known as phosphodiesterase-5 inhibitors (PDE-5). PDE-5 agents are more commonly known as Viagra (sildenafil citrate), Cialis (tadalafil) and Levitra (vardenafil) and are generally considered safe and effective.

For men who do not respond to these oral medications, injectable drugs are available for treatment. Alprostadil, papaverine and phentolamine are drugs that are injected into the corpus cavernosa. These drugs require titration and are initially injected by the physician. Self-injection will ultimately occur after titration has been achieved. Two of these drugs, alprostadil and papaverine, can also be administered through a small catheter into the urethra.

Oral testosterone can reduce ED in some men with low levels of natural testosterone, but it is often ineffective. Studies indicate that although testosterone deficiency may affect the libido, it does not necessarily affect the ability to have erections. Yohimbine hydrochloride and its derivatives Aphrodyne, Testomar, Vigorex, Yocon, and Dayto-Himbin are not FDA approved for this purpose. Other oral drugs, such as dopamine, serotonin agonists, and trazodone, have not been proven to be effective. The results of scientific studies to substantiate these claims have been inconsistent. Despite the fact that herbal remedies are popular worldwide in the treatment of ED, the mechanisms of action, effectiveness, and safety of these agents is questionable. Even the product potency and quality within a given brand may be inconsistent. For men who cannot or do not wish to use drug therapy, an external vacuum device may be an appropriate treatment option. With proper instruction 75% of men can achieve a functional erection.

For more severe disease, usually associated with advanced diabetes, surgical or radiation treatment for prostate or bladder cancer or Peyronie's disease, drug treatment or treatment with an external vacuum device may be ineffective. Implantation of a penile prosthesis is a therapeutic alternative. There are three basic kinds of penile implants: semi-rigid (malleable) implant, two-piece inflatable implant, and three-piece inflatable implant.

Female sexual dysfunction (FSD) can be caused by diabetes, pelvic trauma, hypertension, vascular disease, menopause, or may be idiopathic. Eros clitoral stimulation device is used to obtain greater clitoral engorgement and enhance the ability to achieve an orgasm.

V. CODING INFORMATION

ICD-10 Codes that may apply:

E10.40 – E10.43	Type 1 diabetes mellitus with neurological complications
E10.49	Type 1 diabetes mellitus with other diabetic neurological complication
E10.59	Type 1 diabetes mellitus with other circulatory complications
E10.69	Type 1 diabetes mellitus with other specified complication
E11.40 – E11.43	Type 2 diabetes mellitus with neurological complications
E11.49	Type 2 diabetes mellitus with other diabetic neurological complication
E13.40 – E13.43	Other specified diabetes mellitus with neurological complications
E13.49	Other specified diabetes mellitus with other diabetic neurological complication
I73.9	Peripheral vascular disease, unspecified
N50.1	Vascular disorders of male genital organs
N52.01 – N52.9	Male erectile dysfunction
N94.89	Other specified conditions associated with female genital organs and menstrual cycle
N94.9	Unspecified condition associated with female genital organs and menstrual cycle
N95.8	Other specified menopausal and perimenopausal disorders
N95.9	Unspecified menopausal and perimenopausal disorders
Q52.6	Congenital malformation of clitoris
Q52.8	Other specified congenital malformations of female genitalia
Q52.9	Congenital malformation of female genitalia, unspecified
R10.2	Pelvic and perineal pain
R39.9	Unspecified symptoms and signs involving the genitourinary system
S38.001A – S38.03xS	Crushing injury of external genital organs
S39.840A – S39.848S	Other specified injuries of external genitals
S39.94xA – S39.94xS	Unspecified injury of external genitals

CPT/HCPCS Codes:

Diagnostic

51792	Stimulus evoked response (eg, measurement of bulbocavernosus reflex latency time)
54230	Injection procedure for corpora cavernosography
54231	Dynamic cavernosometry, including intracavernosal injection of vasoactive drugs (e.g., papaverine, phentolamine)
54235	Injection of corpora cavernosa with pharmacologic agent(s) (e.g., papaverine, phentolamine)
J2440*	Injection, papaverine HCl, up to 60 mg

- J2760* Injection, phentolamine mesylate, up to 5 mg
- J0270* Injection, alprostadil, 1.25 mcg (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)
- J0275* Alprostadil urethral suppository (code may be used for Medicare when drug administered under direct supervision of a physician, not for use when drug is self-administered)

** Not covered as a medical drug for these indications for Medicaid or Medicare*

- 54240 Penile plethysmography
- 54250 Nocturnal penile tumescence and/or rigidity test (*Not Covered for Medicaid*)
- 74445 Corpora cavernosography, radiological supervision and interpretation
- 93980 Duplex scan of arterial inflow and venous outflow of penile vessels; complete study
- 93981 Duplex scan of arterial inflow and venous outflow of penile vessels; follow-up or limited study

Surgical Treatments (*Authorization required for Medicaid members only*)

- 54400 Insertion of penile prosthesis; non-inflatable (semi-rigid)
- 54401 Insertion of penile prosthesis; inflatable (self-contained)
- 54405 Insertion of multi-component, inflatable penile prosthesis, including placement of pump, cylinders, and reservoir
- 54410 Removal and replacement of all component(s) of a multi-component, inflatable penile prosthesis at the same operative session
- 54411 Removal and replacement of all components of a multi-component inflatable penile prosthesis through an infected field at the same operative session, including irrigation and debridement of infected tissue
- 54416 Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis at the same operative session
- 54417 Removal and replacement of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis through an infected field at the same operative session, including irrigation and debridement of infected tissue

(No authorization required):

- 54406 Removal of all components of a multi-component, inflatable penile prosthesis without replacement of prosthesis
- 54408 Repair of component(s) of a multi-component, inflatable penile prosthesis
- 54415 Removal of non-inflatable (semi-rigid) or inflatable (self-contained) penile prosthesis, without replacement of prosthesis

Devices

- C1813 Prosthesis, penile, inflatable
- C2622 Prosthesis, penile, non-inflatable
- L7900 Male vacuum erection system (*Not covered for Medicaid or Medicare*)
- E1399 Durable medical equipment, miscellaneous (*for Eros device*)
(*Explanatory notes must accompany claims billed with unlisted codes.*)

Not Covered

0864T Low-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy

ICD-10 Codes *that are not covered for Behavioral Health or medical services:*

F52.0 – F52.9 Sexual dysfunction not due to a substance or known physiological condition
R37 Sexual dysfunction, unspecified

VI. REFERENCES

1. Allahdadi KJ, Tostes RC, Webb RC. Female sexual dysfunction: therapeutic options and experimental challenges. *Cardiovasc Hematol Agents Med Chem.* 2009;7(4):260-269.
2. Aring, A., et al., Evaluation and Prevention of Diabetic Neuropathy, *American Family Physician*, Vol. 71, No. 11, June 1, 2005.
3. American College of Obstetricians and Gynecologists. Female Sexual Dysfunction, Practice Bulletin, Number 213. July 2019
4. American Urological Association (AUA) Erectile Dysfunction: AUA Guideline (2018). Available at [https://www.auanet.org/guidelines-and-quality/guidelines/erectile-dysfunction-\(ed\)-guideline](https://www.auanet.org/guidelines-and-quality/guidelines/erectile-dysfunction-(ed)-guideline) (Accessed June 26, 2025)
5. Centers for Medicare and Medicaid (CMS), [National Coverage Determination \(NCD\) for Diagnosis and Treatment of Impotence \(230.4\)](#) (Accessed June 26, 2025).
6. Cochrane Database of Systematic Reviews, Prostaglandin E1 for treatment of erectile dysfunction, Uriuoli, R., et al., Issue 2, 2006.
7. Feldman, J., and M. Striepe, Women's Sexual Health, *Clinics In Family Practice*, Vol. 6 No. 4, December 2004.
8. McCabe MP, Sharlip ID, Atalla E et al: Definitions of sexual dysfunctions in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. *J Sex Med* 2016; 13: 135.
9. Miller, T. A., Diagnostic Evaluation of Erectile Dysfunction, *American Family Physician*, Vol. 61 No. 1, January 1, 2000.
10. NIH Consensus Statement, Impotence;10 (4), 1-33, 7 Dec 1992. PMID: 1307265
11. Sadovsky, R., and S. Althof, Men's Sexual Issues, Sexual Health, *Clinics In Family Practice*, Vol. 6, No. 4, 863-915, December 2004.
12. Schapiro, R., Managing Symptoms of Multiple Sclerosis, *Neurological Clinics*, Vol., 23, Issue 1,177-187, February 2005.
13. Schroder, M., et al., Clitoral therapy device for treatment of sexual dysfunction in irradiated cervical cancer patients, *Int J Radiat Oncol Biol Phys.*, Vol. 61, Issue 4, 1078-86, March 2005.

APPENDIX A

Likely Causes of Male Erectile Dysfunction Based on Clinical Presentation (This is not an all-inclusive list):

Psychological Causes

- Young age with abrupt onset associated with specific emotional event
- Dysfunction in certain settings while normal function in others
- Persistence of nocturnal erections
- Previous history of erectile dysfunction with spontaneous improvement
- Excessive life stressors—work, relationships
- Mental status findings suggestive of depression, psychosis or anxiety disorder

Organic Causes

- Vasculogenic—arterial
 - Persistent interest in sex
 - Older age with gradual onset
 - Impaired function in all settings
 - Presence of chronic disease (particularly diabetes, hypertension)
 - Use of prescription/over-the-counter medications associated with erectile dysfunction
 - Smoking
 - Elevated blood pressure, evidence of peripheral vascular disease (bruits, decreased pulses, skin and hair changes consistent with arterial insufficiency)
- Vasculogenic—venous
 - Inability to maintain erection once established
 - Prior history of priapism
 - Local anomalies of the penis

Neurogenic Causes

- History of spinal cord/pelvic trauma or surgery
- Presence of chronic disease (diabetes, alcoholism)
- Presence of neurologic condition (multiple sclerosis, stroke)
- Abnormal neurologic examination of genitals/perineum

Hormonal Causes

- Loss of interest in sexual activity
- Small atrophic testis
- Low testosterone, elevated prolactin

AMA CPT Copyright Statement:

All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.

This document is for informational purposes only. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion.

Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.